S'abonner

Invasive Haemophilus influenzae in the United States, 1999–2008: Epidemiology and outcomes - 11/11/12

Doi : 10.1016/j.jinf.2012.08.005 
Daniel J. Livorsi a, b, , Jessica R. MacNeil c, Amanda C. Cohn c, Joseph Bareta d, Shelly Zansky e, Susan Petit f, Ken Gershman g, Lee H. Harrison h, Ruth Lynfield i, Arthur Reingold j, William Schaffner k, Ann Thomas l, Monica M. Farley a,
a Department of Medicine, Emory University School of Medicine, The Atlanta VA Medical Center, 1670 Clairmont Road, Mail Code 151-ID, Atlanta, GA 30333, USA 
b Department of Medicine, Indiana University School of Medicine, USA 
c Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, USA 
d New Mexico Department of Health, USA 
e New York State Department of Health, USA 
f Connecticut Department of Public Health, USA 
g Colorado Department of Public Health and Environment, USA 
h Department of International Health, Johns Hopkins Bloomberg School of Public Health, USA 
i Minnesota Department of Health, USA 
j School of Public Health, University of California, Berkley, USA 
k Department of Preventive Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA 
l Oregon Department of Human Services, USA 

Corresponding author. Indiana University, 545 Barnhill Drive EH 421, Indianapolis, IN 46202, USA. Tel.: +1 317 274 2835; fax: +1 317 274 1587.Corresponding author. Tel.: +1 404 321 6111x2094; fax: +1 404 329 2210.

Summary

Objectives

Introduction of the Haemophilus influenzae type b (Hib) conjugate vaccine has resulted in a dramatic reduction of Hib disease in the U.S. and an increase in the relative importance of infections caused by nontypeable strains. The current project describes the characteristics and clinical outcomes of pediatric and adult patients with invasive H. influenzae (HI) and, through multivariable analysis, identifies risk factors for in-hospital mortality.

Methods

HI cases were identified during 1999–2008 through active surveillance as part of Active Bacterial Core surveillance (ABCs). Multivariable analysis was performed with logistic regression to identify factors predictive of in-hospital death.

Results

4839 cases of HI were identified from 1999–2008. Children accounted for 17.1% of cases and adults 82.9%. Underlying conditions were present in 20.7% of children and 74.8% of adults. In-hospital mortality was highest in cases ≥65 years (21.9%) and <3 months (16.2%).

The risk of in-hospital death in children <1 year was higher among those who were prematurely-born (<28 weeks, OR 7.1, 95% CI 3.2–15.6; 28–36 weeks OR 2.1, 95% CI 0.9–4.8) and, among children aged 1–17 years, higher in those with healthcare-associated onset and dialysis (OR 5.66, 95% CI 1.84–17.39; OR 18.11, 95% CI 2.77–118.65). In adults, age ≥40 was associated with death in nontypeable, but not encapsulated, infections. Infections with nontypeable strains increased the risk of death in cases ≥65 years (OR 1.81, 95% CI 1.31–2.52). Healthcare-associated HI, bacteremia without identifiable focus, bacteremic pneumonia, associated cirrhosis, cerebrovascular accident, dialysis, heart failure, and non-hematologic malignancy also increased the risk of death in adults.

Conclusion

Prematurity in infants, advanced age and certain chronic diseases in adults were associated with an increased risk of in-hospital death. Nontypeable HI was associated with higher mortality in the elderly.

Le texte complet de cet article est disponible en PDF.

Keywords : Haemophilus influenzae, United States, Multivariable analysis, Mortality


Plan


© 2012  The British Infection Association. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 65 - N° 6

P. 496-504 - décembre 2012 Retour au numéro
Article précédent Article précédent
  • Combination of biomarkers for the discrimination between bacterial and viral lower respiratory tract infections
  • Jaap ten Oever, Mirjam Tromp, Chantal P. Bleeker-Rovers, Leo A.B. Joosten, Mihai G. Netea, Peter Pickkers, Frank L. van de Veerdonk
| Article suivant Article suivant
  • Efficacy of linezolid-based salvage therapy compared with glycopeptide-based therapy in patients with persistent methicillin-resistant Staphylococcus aureus bacteremia
  • Hyun Jung Park, Sung-Han Kim, Min-Ju Kim, Yu-Mi Lee, So-Youn Park, Song Mi Moon, Ki-Ho Park, Yong Pil Chong, Sang-Oh Lee, Sang-Ho Choi, Jun Hee Woo, Yang Soo Kim

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.